

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number  
**WO 2005/053796 A1**

(51) International Patent Classification<sup>7</sup>: **A61P 25/24**,  
A61K 31/343, 31/4545, G01N 33/48, A61K 31/00, A61P  
25/00, 25/28, 25/22, 25/16 // (A61K 31/4545, 31:343)

(74) Agent: **BRANTS, Johan, Philippe, Emile**; De Clercq,  
Brants & Partners, E. Gevaertdreef 10A, B-9830  
Sint-Martens-Latem (BE).

(21) International Application Number:  
PCT/BE2004/000172

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(22) International Filing Date: 2 December 2004 (02.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10/725,965	2 December 2003 (02.12.2003)	US
2,451,798	2 December 2003 (02.12.2003)	CA
03447279.5	2 December 2003 (02.12.2003)	EP
04447001.1	5 January 2004 (05.01.2004)	EP
10/752,423	6 January 2004 (06.01.2004)	US
04447066.4	18 March 2004 (18.03.2004)	EP
10/803,793	18 March 2004 (18.03.2004)	US
2,461,248	18 March 2004 (18.03.2004)	CA
04025035.9	21 October 2004 (21.10.2004)	EP
2004-349085	4 November 2004 (04.11.2004)	JP
10/984,683	9 November 2004 (09.11.2004)	US
2,487,529	15 November 2004 (15.11.2004)	CA

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

— *with international search report*  
— *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments*

(71) Applicant (*for all designated States except US*): **B & B  
BEHEER NV** [BE/BE]; Alkerstraat 28, B-3750 Alken  
(BE).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **BUNTINX, Erik**  
[BE/BE]; Alkerstraat 28, B-3750 Alken (BE).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF D4 AND 5-HT<sub>2A</sub> ANTAGONISTS, INVERSE AGONISTS OR PARTIAL AGONISTS

(57) Abstract: The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT<sub>2A</sub> antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability - hypersensitivity - hyperaesthesia - dissociative phenomena - etc). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compounds having 5-HT<sub>2A</sub> antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT<sub>2A</sub> antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.



WO 2005/053796 A1